Literature DB >> 31713082

No superiority of dextrose injections over placebo injections for Osgood-Schlatter disease: a prospective randomized double-blind study.

Junsuke Nakase1, Takeshi Oshima2, Yasushi Takata2, Kengo Shimozaki2, Kazuki Asai2, Hiroyuki Tsuchiya2.   

Abstract

PURPOSE: Osgood-Schlatter disease (OSD) is a traction apophysitis of the tibial tuberosity. Patellar tendinopathy and deep infrapatellar bursitis have recently been shown to contribute to pain in patients with OSD. We compared the effects of dextrose injection and saline injection.
METHODS: We performed a clinical trial from April 2012 to January 2016 and included 49 knees from 37 boys and 1 girl (mean age, 12.3 ± 1.1 years) for whom conventional conservative therapy for > 1 month was ineffective. They were randomly assigned to receive double-blind injections of 1% lidocaine (1 mL) with 20% dextrose (1 mL; dextrose group) or 1% lidocaine (1 mL) with saline (1 mL; saline group). Injections were administered monthly for 3 months by a single investigator. The Victorian Institute of Sport Assessment (VISA) score was used to evaluate anterior knee pain.
RESULTS: Overall, 43 knees were included; 6 knees were lost to follow-up. The mean pre-injection VISA scores in the dextrose and saline groups were 58.7 ± 18.3 and 63.4 ± 16.4, respectively. No significant differences were found between the two groups at any time point. The mean VISA score before injections significantly increased at the 1-month follow-up in both groups (P < .01). The injection had no adverse effects.
CONCLUSIONS: We were not able to show the efficacy of dextrose injections compared to that of saline. LEVEL OF EVIDENCE: Randomized controlled trial. Level I.

Entities:  

Keywords:  Osgood–schlatter disease; Randomized double-blind trial; Ultrasonographic guidance injection

Mesh:

Substances:

Year:  2019        PMID: 31713082     DOI: 10.1007/s00402-019-03297-2

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  5 in total

1.  The posterior tibial slope and Insall-Salvati index in operative and nonoperative adolescent athletes with Osgood-Schlatter disease.

Authors:  Tommy Pan; Frederick Mun; Brandon Martinazzi; Tonya S King; Joseph L Petfield; William L Hennrikus
Journal:  Arch Orthop Trauma Surg       Date:  2022-01-25       Impact factor: 3.067

Review 2.  Osgood-Schlatter Disease: Appearance, Diagnosis and Treatment: A Narrative Review.

Authors:  Francisco Corbi; Sergi Matas; Jesús Álvarez-Herms; Sebastian Sitko; Ernest Baiget; Joaquim Reverter-Masia; Isaac López-Laval
Journal:  Healthcare (Basel)       Date:  2022-05-30

3.  Hyperosmolar dextrose injection for Osgood-Schlatter disease: a double-blind, randomized controlled trial.

Authors:  Zhe Wu; Xiaoxian Tu; Zhiyuan Tu
Journal:  Arch Orthop Trauma Surg       Date:  2021-10-21       Impact factor: 2.928

4.  Nano-Arthroscopic Ultrasound-Guided Excision of Unresolved Osgood-Schlatter Disease.

Authors:  Tomoaki Kamiya; Atsushi Teramoto; Yuta Mori; Chihiro Kitamura; Kota Watanabe; Toshihiko Yamashita
Journal:  Arthrosc Tech       Date:  2021-05-24

5.  Clinical indications for image-guided interventional procedures in the musculoskeletal system: a Delphi-based consensus paper from the European Society of Musculoskeletal Radiology (ESSR)-part V, knee.

Authors:  Luca Maria Sconfienza; Miraude Adriaensen; Domenico Albano; Andrea Alcala-Galiano; Georgina Allen; Maria Pilar Aparisi Gómez; Giacomo Aringhieri; Alberto Bazzocchi; Ian Beggs; Vito Chianca; Angelo Corazza; Danoob Dalili; Miriam De Dea; Jose Luis Del Cura; Francesco Di Pietto; Elena Drakonaki; Fernando Facal de Castro; Dimitrios Filippiadis; Salvatore Gitto; Andrew J Grainger; Simon Greenwood; Harun Gupta; Amanda Isaac; Slavcho Ivanoski; Monica Khanna; Andrea Klauser; Ramy Mansour; Silvia Martin; Vasco Mascarenhas; Giovanni Mauri; Catherine McCarthy; David McKean; Eugene McNally; Kalliopi Melaki; Rebeca Mirón Mombiela; Ricardo Moutinho; Marina Obradov; Cyprian Olchowy; Davide Orlandi; Raquel Prada González; Mahesh Prakash; Magdalena Posadzy; Saulius Rutkauskas; Žiga Snoj; Alberto Stefano Tagliafico; Alexander Talaska; Xavier Tomas; Violeta Vasilevska-Nikodinovska; Jelena Vucetic; David Wilson; Federico Zaottini; Marcello Zappia; Carmelo Messina
Journal:  Eur Radiol       Date:  2021-09-14       Impact factor: 5.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.